U.S. Physical Therapy (USPH) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of
.1B, trading at $73.28 on the NYSE. This SniperIQ fundamentals page covers U.S. Physical Therapy's valuation (P/E 146.6x, P/B 2.4x), profitability (net margin 0.2%), revenue ($781M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
.1B
P/E (TTM)146.6x
Net Margin0.2%
Revenue (FY25)$781M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is U.S. Physical Therapy's market cap?
U.S. Physical Therapy (USPH) has a market capitalization of approximately
.1B, trading at $73.28 on the NYSE. Market cap moves with the live share price.
What is U.S. Physical Therapy's P/E ratio?
U.S. Physical Therapy's trailing twelve-month P/E ratio is 146.6x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is U.S. Physical Therapy?
U.S. Physical Therapy runs a net profit margin of 0.2%, a gross margin of 20.4%, and an operating margin of 12.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does U.S. Physical Therapy generate?
U.S. Physical Therapy reported revenue of $781M for fiscal year 2025, with net income of
5M and earnings per share (EPS) of 1.42. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does U.S. Physical Therapy pay a dividend?
U.S. Physical Therapy offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is U.S. Physical Therapy financially healthy?
U.S. Physical Therapy carries a debt-to-equity ratio of 0.77x and a current ratio of 1.19x, with a market beta of 1.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is U.S. Physical Therapy a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For U.S. Physical Therapy (USPH) the key facts are: market cap
.1B, P/E 146.6x, revenue $781M, 52-week range 58.19-93.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track U.S. Physical Therapy's full fundamentals live
Get U.S. Physical Therapy's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.